Literature DB >> 19682755

Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression.

Islam A Saleh1, Theresa Zesiewicz, Yong Xie, Kelly L Sullivan, Amber M Miller, Nicole Kuzmin-Nichols, Paul R Sanberg, Svitlana Garbuzova-Davis.   

Abstract

In ALS, evidence suggests immune reactions in disease pathogenesis. Although immunological changes point to adaptive immune response, whether humoral or cellular response dominates during disease course is unknown. The study aim was to evaluate humoral immune response in ALS patients during disease progression. Circulating immune complexes (CICs), IgG, and IgM in sera of ALS patients and matching controls were evaluated after each of two visits. Results showed significantly elevated CICs and IgG in ALS patient sera. CICs decreased to control levels at the second visit, yet IgG remained higher than controls. Serum IgM was within normal range. Results suggest a humoral immune response initiating adaptive immunity in ALS, however, cellular immune response needs verification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682755     DOI: 10.1016/j.jneuroim.2009.07.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and Disease.

Authors:  Kathryn J Jones; Amy E Lovett-Racke; Chandler L Walker; Virginia M Sanders
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-07       Impact factor: 4.147

Review 2.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

3.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 4.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 5.  The Role of immune and inflammatory mechanisms in ALS.

Authors:  P A McCombe; R D Henderson
Journal:  Curr Mol Med       Date:  2011-04       Impact factor: 2.222

6.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

7.  Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis.

Authors:  Mengli Wang; Zhen Liu; Juan Du; Yanchun Yuan; Bin Jiao; Xuewei Zhang; Xuan Hou; Lu Shen; Jifeng Guo; Hong Jiang; Kun Xia; Jianguang Tang; Ruxu Zhang; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

8.  Humoral immune activation in amyotrophic lateral sclerosis patients.

Authors:  Michael Rentzos; Maria Eleftheria Evangelopoulos; Eleni Sereti; Vassiliki Zouvelou; Styliani Marmara; Theodoros Alexakis; Ioannis Evdokimidis
Journal:  Neurol Int       Date:  2013-02-11

Review 9.  Blood-CNS Barrier Impairment in ALS patients versus an animal model.

Authors:  Svitlana Garbuzova-Davis; Paul R Sanberg
Journal:  Front Cell Neurosci       Date:  2014-02-03       Impact factor: 5.505

Review 10.  Novel molecular biomarkers at the blood-brain barrier in ALS.

Authors:  Danijela Bataveljic; Milena Milosevic; Lidija Radenovic; Pavle Andjus
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.